Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy
Astellas Pharma Inc. (TSE: 4503) and Osaka University have announced a research collaboration to develop an innovative pluripotent stem cell-derived cartilage organoid cell therapy for treating intervertebral disc degenerative disease. The partnership combines:
- Osaka University's cartilage tissue creation protocol
- Universal Cells' Universal Donor Cell (UDC) technology
- Astellas Institute for Regenerative Medicine's R&D expertise in cell therapy
This collaboration aims to create a cell therapy with reduced risk of immune rejection by genetically modifying Human Leukocyte Antigen (HLA) using gene editing technology. The partnership represents a significant step in open innovation using UDC technology to develop regenerative therapies for intervertebral disc degenerative disease.
Astellas Pharma Inc. (TSE: 4503) e l'Università di Osaka hanno annunciato una collaborazione di ricerca per sviluppare una innovativa terapia cellulare a base di organoidi derivati da cellule staminali pluripotenti per il trattamento della malattia degenerativa del disco intervertebrale. La collaborazione combina:
- il protocollo di creazione di tessuto cartilagineo dell'Università di Osaka
- la tecnologia Universal Donor Cell (UDC) di Universal Cells
- l'expertise in R&D dell'Astellas Institute for Regenerative Medicine nel campo della terapia cellulare
Questa collaborazione mira a creare una terapia cellulare con un rischio ridotto di rigetto immunitario attraverso la modifica genetica dell'Antigene Leucocitario Umano (HLA) utilizzando tecnologie di editing genetico. La partnership rappresenta un passo significativo nell'innovazione aperta, utilizzando la tecnologia UDC per sviluppare terapie rigenerative per la malattia degenerativa del disco intervertebrale.
Astellas Pharma Inc. (TSE: 4503) y la Universidad de Osaka han anunciado una colaboración en investigación para desarrollar una innovadora terapia celular de organoides derivados de células madre pluripotentes para el tratamiento de la enfermedad degenerativa del disco intervertebral. La asociación combina:
- el protocolo de creación de tejido cartilaginoso de la Universidad de Osaka
- la tecnología Universal Donor Cell (UDC) de Universal Cells
- la experiencia en I+D del Astellas Institute for Regenerative Medicine en terapia celular
Esta colaboración tiene como objetivo crear una terapia celular con un riesgo reducido de rechazo inmunológico mediante la modificación genética del Antígeno Leucocitario Humano (HLA) utilizando tecnología de edición genética. La asociación representa un paso importante en la innovación abierta utilizando la tecnología UDC para desarrollar terapias regenerativas para la enfermedad degenerativa del disco intervertebral.
Astellas Pharma Inc. (TSE: 4503)와 오사카 대학은 연구 협력을 발표하여 다능성 줄기세포 유래 연골 오르가노이드 세포 치료법을 개발하여 척추 디스크 퇴행성 질환을 치료하고자 합니다. 이 파트너십은 다음을 결합합니다:
- 오사카 대학의 연골 조직 생성 프로토콜
- Universal Cells의 Universal Donor Cell (UDC) 기술
- Astellas Institute for Regenerative Medicine의 세포 치료 연구 및 개발 전문성
이 협력은 유전자 편집 기술을 사용하여 인간 백혈구 항원(HLA)을 유전적으로 수정함으로써 면역 거부 반응 위험을 줄인 세포 치료법을 만드는 것을 목표로 합니다. 이 파트너십은 UDC 기술을 사용하여 척추 디스크 퇴행성 질환을 위한 재생 치료법을 개발하는 데 있어 열린 혁신의 중요한 단계를 나타냅니다.
Astellas Pharma Inc. (TSE: 4503) et l'Université d'Osaka ont annoncé une collaboration en recherche pour développer une thérapie cellulaire à base d'organoïdes dérivés de cellules souches pluripotentes pour traiter la maladie dégénérative des disques intervertébraux. Le partenariat combine :
- le protocole de création de tissu cartilagineux de l'Université d'Osaka
- la technologie Universal Donor Cell (UDC) de Universal Cells
- l'expertise en R&D de l'Astellas Institute for Regenerative Medicine dans le domaine de la thérapie cellulaire
Cette collaboration vise à créer une thérapie cellulaire avec un risque réduit de rejet immunitaire en modifiant génétiquement l'Antigène Leucocytaire Humain (HLA) à l'aide de technologies d'édition génique. Ce partenariat représente une avancée significative en innovation ouverte en utilisant la technologie UDC pour développer des thérapies régénératives pour la maladie dégénérative des disques intervertébraux.
Astellas Pharma Inc. (TSE: 4503) und die Universität Osaka haben eine Forschungspartnerschaft angekündigt, um eine innovative zelluläre Therapie auf Basis von pluripotenten Stammzellen abgeleiteten Knorpelorganoiden zur Behandlung der degenerativen Erkrankung der Bandscheiben zu entwickeln. Die Partnerschaft kombiniert:
- das Protokoll zur Erstellung von Knorpelgewebe der Universität Osaka
- die Universal Donor Cell (UDC) Technologie von Universal Cells
- die Forschung und Entwicklungskompetenz des Astellas Institute for Regenerative Medicine im Bereich der Zelltherapie
Diese Zusammenarbeit zielt darauf ab, eine Zelltherapie mit reduziertem Risiko einer immunologischen Abstoßung durch genetische Modifikation des menschlichen Leukozyten-Antigens (HLA) mithilfe von Gentechnologie zu schaffen. Die Partnerschaft stellt einen bedeutenden Schritt in der offenen Innovation dar, die UDC-Technologie zur Entwicklung regenerativer Therapien für die degenerative Erkrankung der Bandscheiben zu nutzen.
- Collaboration with leading academic institution (Osaka University) for innovative cell therapy development
- Potential to create a cell therapy with reduced risk of immune rejection
- Combining expertise in cartilage tissue creation, UDC technology, and cell therapy R&D
- None.
- Collaborative Research on Innovative Cartilage Organoid Cell Therapy for Intervertebral Disc Degenerative Disease using Astellas' Universal Donor Cell Technology -
TOKYO and
Universal Cells holds the rights to Universal Donor Cell (UDC) technology to create cell therapy products from pluripotent stem cells that have reduced risk of immune rejection by genetically modifying Human Leukocyte Antigen (HLA) using gene editing technology.
Under the terms of the agreement, the three parties aim to combine the cartilage tissue creation protocol established by Professor Noriyuki Tsumaki of (Graduate School of Frontier Biosciences / Premium Research Institute for Human Metaverse Medicine) the Department of Tissue Biochemistry and Molecular Biology, Graduate School of Medicine,
Yoshitsugu Shitaka, Ph.D., Chief Scientific Officer (CScO) of Astellas
"Astellas is committed to achieving our VISION of being "on the forefront of healthcare change, turning innovative science into VALUE for patients". We hope to provide our cutting-edge UDC technology to academia and startups globally, and deliver next-generation cell therapies to patients. This partnership is an important step in the open innovation using UDC technology."
Professor Noriyuki Tsumaki, M.D., Ph.D., (Graduate School of Frontier Biosciences / Premium Research Institute for Human Metaverse Medicine) Department of Tissue Biochemistry and Molecular Biology, Graduate School of Medicine,
"We believe that our cartilage-like tissue has the potential to regenerate intervertebral discs. We hope that combining our research with Astellas' UDC technology and R&D cell therapy system will accelerate and realize the development of regenerative therapies to treat intervertebral disc degenerative disease."
*1 Pluripotent stem cell: Cells that possess the ability to proliferate almost indefinitely and differentiate into any cell that makes up the organism. Ex. embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells).
*2 Intervertebral disc degenerative disease: A type of degenerative spinal disease. The intervertebral discs, which are cartilaginous tissues, play a crucial role as cushions between each bone of the spine by containing a significant amount of water. This helps maintain flexible movement of the back. However, when these discs degenerate, they lose water, resulting in the failure of their cushioning function, which can lead to lower back pain.
About Astellas
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at https://www.astellas.com/en.
Cautionary Notes (Astellas)
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
View original content to download multimedia:https://www.prnewswire.com/news-releases/astellas-and-graduate-school-of-medicine--faculty-of-medicine-osaka-university-enter-into-research-collaboration-to-develop-pluripotent-stem-cell-derived-cartilage-organoid-cell-therapy-302202390.html
SOURCE ASTELLAS PHARMA INC.
FAQ
What is the purpose of the research collaboration between Astellas (ALPMY) and Osaka University?
How does the Universal Donor Cell (UDC) technology used in this Astellas (ALPMY) collaboration work?
What is intervertebral disc degenerative disease, the target of Astellas' (ALPMY) new cell therapy research?
Who are the key parties involved in the Astellas (ALPMY) cartilage organoid cell therapy research collaboration?
